Lancet review: mRNA COVID-19 vaccines safe and highly effective

COVID-19 mRNA vaccines are safe and highly effective, offering robust protection against infection, hospitalization, and death, a comprehensive review published in The Lancet confirms. The study, which analyzed billions of vaccine doses administered globally, found an approximate 87% efficacy against symptomatic infection, 93% against hospitalization, and 94% against death within 14 to 42 days post-vaccination.

While the protective immunity diminishes over time and differs across age groups, the review highlights that booster doses effectively restore this protection. Ongoing monitoring of data indicates that protection is maintained even with the emergence of new virus variants. This reinforces the strong scientific evidence supporting the excellent safety profile of mRNA vaccines, with severe adverse events being exceptionally rare.

Incidents of myocarditis and pericarditis, though slightly more common after the second dose, occurred at rates of approximately 12.6 per million doses for Pfizer and 35.6 per million for Moderna. The review emphasizes that the benefit of preventing severe illness, hospitalization, and death significantly outweighs these potential risks. The increased risk of myocarditis or pericarditis, particularly in males aged 12-19, remains substantially lower than the risk associated with SARS-CoV-2 infection itself. Other severe side effects, such as anaphylaxis and Guillain-Barre syndrome, were also found to be very rare.

The review also points to the broader potential of mRNA technology. Researchers suggest it could pave the way for new vaccines against influenza, respiratory syncytial virus (RSV), and other infectious diseases. Furthermore, the technology holds promise for developing personalized cancer vaccines and RNA-based therapies. The study authors stress the importance of equitable vaccine access, enhancing production in low- and middle-income countries, and improving storage and distribution infrastructure. Clear, evidence-based public communication about vaccine safety and efficacy is also deemed critical for building public trust and combating misinformation.